The next steps and updated guidelines for the use of MRD concepts in multiple myeloma
Drug–drug interactions & the potential impact on toxicity levels in patients with B-cell malignancy
The explosion of immuno-oncology
How to address the issue of access to new drugs in multiple myeloma
Paul Richardson et al.
MAJIC trial results: ruxolitinib compared to best available therapy for essential thrombocythemia